Navigation Links
New platinum-phosphate compounds kill ovarian cancer cells
Date:11/19/2008

ATHENS, Ohio (Nov. 19, 2008) A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences.

The compounds could be less harmful than current cancer treatments on the market such as cisplatin and carboplatin because they don't penetrate the cell nucleus and attach to DNA, said lead author Rathindra Bose. Conventional drugs can interfere with the functions of the cell's enzymes, which lead to side effects such as hearing and hair loss and kidney dysfunction.

Though scientists don't fully understand the mechanism by which the phosphaplatins kill cancer cells, they suspect that the compounds bind to the cell surface membrane proteins and transmit a "death signal" to the interior of the cell, Bose said. The compounds are created by attaching platinum to a phosphate ligand, which can readily anchor to the cell membrane. Future studies will focus on identifying the exact process.

"The findings suggest a paradigm shift in potential molecular targets for platinum anticancer drugs and in their strategic development," said Bose, a professor of biomedical sciences and chemistry and vice president for research at Ohio University who conducted the work while at Northern Illinois University.

The first drug developed for the treatment of ovarian and testicular cancers, cisplatin, was approved for use in 1982. Though it's 95 percent effective, it works best during the early stages of the disease, and some patients develop a resistance to it. Two drugs introduced later, carboplatin and oxaliplatin (which is used for colorectal cancer), overcame some of those problems, but their potency can harm the immune system of patients, said Bose, who has been studying alternative compounds and targets for these cancers for 25 years.

Phosphaplatins have the potential to be more efficient, more targeted and create fewer side effects in the patient, Bose said. The new study shows that the phosphaplatins can kill ovarian cells at half of the dosage of conventional drugs, but are just as potent. Unlike cisplatin, which can decompose quickly and create additional toxic side effects through the decomposition products, the new compounds show no signs of degradation after seven days, he added.

A U.S. patent is pending on the work; two provisional patents have been filed. Bose and his colleagues next will test the compounds in mice models.


'/>"/>

Contact: Andrea Gibson
gibsona@ohio.edu
740-597-2166
Ohio University
Source:Eurekalert

Related medicine news :

1. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
2. Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
3. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
4. Novel Compounds May Battle Diseases of Aging
5. Bionovo Describes a New Class of Therapeutic Compounds
6. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer
7. Research discovers new compounds active against tuberculosis and malaria
8. Researcher of the University of Navarra discovered potential antidepressant compounds
9. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
10. Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands
11. Drosophila drug screen for fragile X syndrome finds promising compounds and potential drug targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... Coppin ... business owners and families in and around the Cape Coral area, is embarking on ... Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest ...
(Date:12/8/2016)... Fort Payne, AL (PRWEB) , ... December 08, ... ... enterprise offering insurance and financial consulting services to residential and commercial clients in ... raise awareness and support for Nobis Works. , Since 1977, Nobis Works has ...
(Date:12/7/2016)... ... , ... DrugDev again demonstrated its dedication to reducing the administrative ... adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. , ... the Atlantic with a mechanism to comply with EU data protection requirements when transferring ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and ... comprehensive mental health systems reform legislation in more than fifty years. We applaud ... commitment of our elected officials to improving mental health services and supports in ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... drug in their bodies, a researcher at the Icahn School of Medicine at ... , The study found that when young children are exposed to secondhand marijuana ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... grow in 2017-2023. Various reasons for growth of the ... higher incidences of chronic diseases, high recovery cost of ... services. Medical lifting sling refers to an assistive ... mobility. These slings connect to the lift and hold ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... diagnostics includes products and tests that are used ... grass, weed, peanuts, milk, or drugs etc. in ... developed by the immune system. The report on ... future prospects of the market. The report consists ...
Breaking Medicine Technology: